This study tests a new drug combination (AGEN1423 and botensilimab) with or without chemotherapy in people with advanced pancreatic cancer that has worsened after at least one prior treatment. The goal is to see if the combination can shrink tumors or slow the disease. About 24 a…
Phase: PHASE2 • Sponsor: Bruno Bockorny • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC